Veru's drug helps older Wegovy patients preserve muscle in study
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Veru's experimental drug helps older obese patients on Wegovy preserve muscle
Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
STAT2d
Veru says its drug preserved lean mass in patients taking Wegovy
An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...
BioSpace2d
Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough?
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
pharmaphorum1d
Veru shares plunge despite positive data in obesity trial
The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
BioPharma Dive2d
Muscle-building drug improves body composition in obesity trial, Veru says
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
STAT2d
U.S. health agencies see some chaos — but an FDA approval gets through
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
ENDPOINTS NEWS2d
Veru's drug lessens loss of lean mass in pa­tients tak­ing We­govy
Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...
Veru Reports Positive Data From Phase 2b QUALITY Study
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company Monday announced positive topline results from the Phase 2b ...
Veru’s enobosarm meets primary endpoint in Phase 2b weight reduction trial
Veru (VERU) announced positive topline results from the Phase 2b QUALITY clinical study. The Phase 2b QUALITY clinical study was ...
BioWorld3d
Veru weight loss study hits primary endpoint, stock drops
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). The side effect of lean mass ...